Method of preventing adverse effects by GLP-1
US8377869B2 · kind B2 · utility
55Cited by
73References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 24, 2008 |
| Grant date | Feb 19, 2013 |
| Priority date | — |
| Expiry date | Dec 11, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.